381 related articles for article (PubMed ID: 25855785)
21. FBXW7 mediates chemotherapeutic sensitivity and prognosis in NSCLCs.
Yokobori T; Yokoyama Y; Mogi A; Endoh H; Altan B; Kosaka T; Yamaki E; Yajima T; Tomizawa K; Azuma Y; Onozato R; Miyazaki T; Tanaka S; Kuwano H
Mol Cancer Res; 2014 Jan; 12(1):32-7. PubMed ID: 24165483
[TBL] [Abstract][Full Text] [Related]
22. MicroRNA-25 promotes gastric cancer proliferation, invasion, and migration by directly targeting F-box and WD-40 Domain Protein 7, FBXW7.
Gong J; Cui Z; Li L; Ma Q; Wang Q; Gao Y; Sun H
Tumour Biol; 2015 Sep; 36(10):7831-40. PubMed ID: 25944166
[TBL] [Abstract][Full Text] [Related]
23. Tumor-suppressor Fbxw7 targets SIK2 for degradation to interfere with TORC2-AKT signaling in pancreatic cancer.
Zhang MX; Wang H; Sun GP
Cell Biol Int; 2020 Sep; 44(9):1900-1910. PubMed ID: 32437091
[TBL] [Abstract][Full Text] [Related]
24. The sensitivity of gastric cancer to trastuzumab is regulated by the miR-223/FBXW7 pathway.
Eto K; Iwatsuki M; Watanabe M; Ishimoto T; Ida S; Imamura Y; Iwagami S; Baba Y; Sakamoto Y; Miyamoto Y; Yoshida N; Baba H
Int J Cancer; 2015 Apr; 136(7):1537-45. PubMed ID: 25159729
[TBL] [Abstract][Full Text] [Related]
25. Copy number loss of FBXW7 is related to gene expression and poor prognosis in esophageal squamous cell carcinoma.
Yokobori T; Mimori K; Iwatsuki M; Ishii H; Tanaka F; Sato T; Toh H; Sudo T; Iwaya T; Tanaka Y; Onoyama I; Kuwano H; Nakayama KI; Mori M
Int J Oncol; 2012 Jul; 41(1):253-9. PubMed ID: 22576686
[TBL] [Abstract][Full Text] [Related]
26. Wnt/β-catenin signaling inhibits FBXW7 expression by upregulation of microRNA-770 in hepatocellular carcinoma.
Wu WJ; Shi J; Hu G; Yu X; Lu H; Yang ML; Liu B; Wu ZX
Tumour Biol; 2016 May; 37(5):6045-51. PubMed ID: 26602384
[TBL] [Abstract][Full Text] [Related]
27. Rapamycin inhibits FBXW7 loss-induced epithelial-mesenchymal transition and cancer stem cell-like characteristics in colorectal cancer cells.
Wang Y; Liu Y; Lu J; Zhang P; Wang Y; Xu Y; Wang Z; Mao JH; Wei G
Biochem Biophys Res Commun; 2013 May; 434(2):352-6. PubMed ID: 23558291
[TBL] [Abstract][Full Text] [Related]
28. FBXW7 is involved in the acquisition of the malignant phenotype in epithelial ovarian tumors.
Kitade S; Onoyama I; Kobayashi H; Yagi H; Yoshida S; Kato M; Tsunematsu R; Asanoma K; Sonoda K; Wake N; Hata K; Nakayama KI; Kato K
Cancer Sci; 2016 Oct; 107(10):1399-1405. PubMed ID: 27486687
[TBL] [Abstract][Full Text] [Related]
29. Tumor suppressor Fbxw7 antagonizes WNT signaling by targeting β-catenin for degradation in pancreatic cancer.
Jiang JX; Sun CY; Tian S; Yu C; Chen MY; Zhang H
Tumour Biol; 2016 Oct; 37(10):13893-13902. PubMed ID: 27485116
[TBL] [Abstract][Full Text] [Related]
30. FBXW7 acts as an independent prognostic marker and inhibits tumor growth in human osteosarcoma.
Li Z; Xiao J; Hu K; Wang G; Li M; Zhang J; Cheng G
Int J Mol Sci; 2015 Jan; 16(2):2294-306. PubMed ID: 25622249
[TBL] [Abstract][Full Text] [Related]
31. FBXW7 mutation analysis and its correlation with clinicopathological features and prognosis in colorectal cancer patients.
Chang CC; Lin HH; Lin JK; Lin CC; Lan YT; Wang HS; Yang SH; Chen WS; Lin TC; Jiang JK; Chang SC
Int J Biol Markers; 2015 Feb; 30(1):e88-95. PubMed ID: 25450649
[TBL] [Abstract][Full Text] [Related]
32. MiR-223 promotes the doxorubicin resistance of colorectal cancer cells via regulating epithelial-mesenchymal transition by targeting FBXW7.
Ding J; Zhao Z; Song J; Luo B; Huang L
Acta Biochim Biophys Sin (Shanghai); 2018 Jun; 50(6):597-604. PubMed ID: 29701752
[TBL] [Abstract][Full Text] [Related]
33. Circadian Amplitude Regulation via FBXW7-Targeted REV-ERBα Degradation.
Zhao X; Hirota T; Han X; Cho H; Chong LW; Lamia K; Liu S; Atkins AR; Banayo E; Liddle C; Yu RT; Yates JR; Kay SA; Downes M; Evans RM
Cell; 2016 Jun; 165(7):1644-1657. PubMed ID: 27238018
[TBL] [Abstract][Full Text] [Related]
34. CDK5/FBW7-dependent ubiquitination and degradation of EZH2 inhibits pancreatic cancer cell migration and invasion.
Jin X; Yang C; Fan P; Xiao J; Zhang W; Zhan S; Liu T; Wang D; Wu H
J Biol Chem; 2017 Apr; 292(15):6269-6280. PubMed ID: 28242758
[TBL] [Abstract][Full Text] [Related]
35. Role of Fbxw7 expression in hepatocellular carcinoma and adjacent non-tumor liver tissue.
Imura S; Tovuu LO; Utsunomiya T; Morine Y; Ikemoto T; Arakawa Y; Kanamoto M; Iwahashi S; Saito Y; Takasu C; Yamada S; Ishikawa D; Bando Y; Shimada M
J Gastroenterol Hepatol; 2014 Oct; 29(10):1822-9. PubMed ID: 24731221
[TBL] [Abstract][Full Text] [Related]
36. Distinct Interactions of EBP1 Isoforms with FBXW7 Elicits Different Functions in Cancer.
Wang Y; Zhang P; Wang Y; Zhan P; Liu C; Mao JH; Wei G
Cancer Res; 2017 Apr; 77(8):1983-1996. PubMed ID: 28209614
[TBL] [Abstract][Full Text] [Related]
37. Loss of CDC4/FBXW7 in gastric carcinoma.
Milne AN; Leguit R; Corver WE; Morsink FH; Polak M; de Leng WW; Carvalho R; Offerhaus GJ
Cell Oncol; 2010; 32(5-6):347-59. PubMed ID: 20448329
[TBL] [Abstract][Full Text] [Related]
38. Nuclear orphan receptor NR4A2 confers chemoresistance and predicts unfavorable prognosis of colorectal carcinoma patients who received postoperative chemotherapy.
Han Y; Cai H; Ma L; Ding Y; Tan X; Liu Y; Su T; Yu Y; Chang W; Zhang H; Fu C; Cao G
Eur J Cancer; 2013 Nov; 49(16):3420-30. PubMed ID: 23809767
[TBL] [Abstract][Full Text] [Related]
39. FBW7 mutations mediate resistance of colorectal cancer to targeted therapies by blocking Mcl-1 degradation.
Tong J; Tan S; Zou F; Yu J; Zhang L
Oncogene; 2017 Feb; 36(6):787-796. PubMed ID: 27399335
[TBL] [Abstract][Full Text] [Related]
40. Increased incidence of FBXW7 and POLE proofreading domain mutations in young adult colorectal cancers.
Kothari N; Teer JK; Abbott AM; Srikumar T; Zhang Y; Yoder SJ; Brohl AS; Kim RD; Reed DR; Shibata D
Cancer; 2016 Sep; 122(18):2828-35. PubMed ID: 27244218
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
